The OWLiver® test is a serum-based non-invasive diagnostic method that, by means of a lipidomic analysis of fasting blood samples, allows:
The lipids of the OWLiver® panel are determined by high performance liquid chromatography coupled to mass spectrometry (UHPLC-MS). The relative concentrations of these lipids, together with ALT, AST and body mass index (BMI), are analyzed together in three algorithms that reflect the liver fat content, inflammation, and fibrosis.
The OWLiver® panel has been developed to estimate the stage of MASLD and is based on a prospective study in which patients had been previously diagnosed using the gold standard for this disease, liver biopsy. The OWLiver® panel was developed in a multicenter and multiethnic study, which included patients with a BMI greater than 25 kg / m2 and with different degrees of type 2 diabetes mellitus, including non-diabetics, controlled diabetics and diabetics with poor glycemic control.
Developed by Rubió Metabolomics, S.L.U., the OWLiver® Panel is a CE-marked in vitro diagnostic medical device, complying with Directive 98/79/EC.
For more information contact: owliver@labrubio.com
In vitro diagnostic medical device with CE marking.
Marketed and distributed by Cima Sciences in the USA (https://cimasciences.com/) and by Rubió Metabolomics in the rest of the world (https://owlmetabolomics.com/).
Developed by: Rubió Metabolomics, S.L.U.
Ownership: Rubió Metabolomics, S.L.U.
The information contained in this area is directed exclusively to healthcare professionals with the capacity to prescribe or dispense medications.
